BOSTON, MA--(NewMediaWire - Jan 6, 2017) - Cannabis Science,
Inc. (OTC PINK: CBIS), a U.S. company specializing in the
development of cannabinoid-based medications, is proud to announce
a collaborative research agreement with Dana Farber/Harvard Cancer
Center (DF/HCC). The agreement lays the foundation for a
cooperative research initiative to explore and develop new
cannabinoid medicines to fight cancer. This agreement is also the
first step in the development of clinical trials that will lead to
approval of successful cannabinoids by the FDA.
"We believe that collaborative cutting-edge work is the most
powerful approach in fighting cancer. This collaborative agreement
brings together the expertise of a leading Cannabis Research
Company, Cannabis Science, and the research strength of Dana
Farber/Harvard Cancer Center. I can see how this collaboration with
Cannabis Science will grow as we work together for
commercialization of joint research successes, with ultimate goal
of translating these successes to benefit cancer patients in the
USA and across the globe. So, I'm excited to get started setting up
what could become a leading Cannabis Science Institute lab under my
direction here at the Harvard Institute of Medicine. Under this
agreement, Cannabis Science will have access to the best expertise
within Dana Farber/Harvard Cancer Center to help develop multiple
preclinical and clinical cannabinoid compounds. As we progress, we
can bring cannabinoid cancer compounds to clinical trials and to
FDA approval process quickly and efficiently. So many patients
still die of cancer, hence our urgency and obligation to swiftly
pursue cutting-edge research that can benefit patients," stated,
Professor Wilfred Ngwa, PhD., Director, Global Health Catalyst,
Dana Farber/Harvard Cancer Center.
"The goal of this research project is to develop and investigate
the use of Cannabinoids in the treatment of a variety of cancers,
and investigate the synergistic impact of cannabinoids when used
together with standard and novel anti-cancer regimens. We believe
that cannabinoid therapeutics must be refined and we hypothesize
that cannabinoids can optimize standard and novel anti-cancer
treatments, including those that train the immune system to fight
cancer metastasis, i.e. cancer spread to other parts of the body.
Metastasis accounts for over 90% of cancer deaths and associated
pain and suffering; hence, if we are successful, this could lead to
major increase in survival and quality of life for cancer patients
in the USA and across the world.
"The results of our work should give us a much better
understanding of how cannabinoids interact with cancer and immune
cell populations, and to leverage this knowledge to develop refined
and optimized combination of cannabinoids, specifically designed to
combat the spread of cancer. We will extract/analyze and refine
cannabinoids for in-vivo investigations. We will refine the
cannabinoids to superior grade level for medical application and
then examine their effectiveness in a precisely targeted delivery
system, designed to maximize damage to cancer cells with minimal
side effects.
"Findings from this collaborative research will be expeditiously
submitted to leading peer-reviewed journals, and resulting
publications will be widely disseminated to the public.
Publications will be jointly authored with authorship credits based
on contributions, as per academic standards and customs.
Additionally, any treatments, inventions conceived, and other
intellectual property that is the result of this collaboration will
be jointly owned by the CBIS and DF/HCC, and this includes patents
on medications and delivery methods," stated, Dr. Allen A. Herman,
Chief Medical Officer (CMO), Cannabis Science Inc.
"We are so excited to be able to announce our collaboration with
one of the most esteemed cancer research institutions in the world.
2017 is setting up to be the biggest year for the Company and
Shareholders since our inception in 2009, and this collaboration
with DF/HCC is one more step that Cannabis Science is taking to
increase shareholder value. Our intentions are simple: provide
improved quality of life, and create knowledge. This is a new kind
of collaboration between a comprehensive bricks and mortar cancer
research center like DF/HCC that has years of expertise and
understanding of cancer research and treatments, and a cutting-edge
cannabinoid research and development Company like CBIS with
aggressive plans to leverage our expertise in the chemical makeup
of cannabinoids to develop highly effective cannabinoid-based
cancer treatments", stated Cannabis Science Inc., President &
CEO, Mr. Raymond C. Dabney.
About Dana Farber/Harvard Cancer Center
http://www.dfhcc.harvard.edu
Dana-Farber/Harvard Cancer Center (DF/HCC), an NCI-designated
comprehensive cancer center, was founded to integrate and build
upon the collective talent and resources of the Harvard cancer
research community.
Five Boston academic medical institutions -- Beth Israel
Deaconess Medical Center, Boston Children's Hospital, Brigham and
Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts
General Hospital -- and two Harvard Schools -- the Harvard Medical
School and the Harvard T.H. Chan School of Public Health --
combined their scientific strengths to create a rich, collaborative
environment that transcends institutional borders. DF/HCC is the
powerful successor organization to the Dana-Farber Cancer Institute
Comprehensive Cancer Center, one of the original cancer centers
designated by the NCI in 1973.
Today, more than 1,100 DF/HCC cancer researchers are working
together in innovative clinical-, translational-, basic-, and
population-based research programs. Our members receive in excess
of $600 million in cancer research funding. Cost-effective shared
facilities, or centralized core laboratories, enable access to
cutting edge technologies and allow us to build world-class
scientific archives. Thousands of patients are being enrolled in
our clinical trials. Our members are training and educating the
next generation of cancer researchers.
As one of the largest cancer research enterprises in the world,
DF/HCC is committed to maximizing the impact of its research for
cancer patients and ultimately realizing a world without
cancer.
About Cannabis Science Inc.
Cannabis Science, Inc., takes advantage of its unique understanding
of metabolic processes to provide novel treatment approaches to
several illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history
dating back thousands of years, and currently, there are a growing
number of peer-reviewed scientific publications that document the
underlying biochemical pathways that cannabinoids modulate. The
Company works with leading experts in drug development, medicinal
characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on skin cancers, HIV/AIDS, and neurological
conditions. The Company is proceeding with the research and
development of its proprietary drugs as a part of this initial
focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements. Safe Harbor
Statement. The Private Securities Litigation Reform Act of 1995
provides a 'safe harbor' for forward looking statements. Certain of
the statements contained herein, which are not historical facts are
forward looking statements with respect to events, the occurrence
of which involved risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by
various factors. Information concerning potential factors that
could affect the company are detailed from time to time in the
company's reports filed with the Securities and Exchange
Commission.